ArticleNature2021
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 102 papers.
0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 145 citations in OpenAlex.
- Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.Emerging microbes & infections · 2024Trial
- A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV.Emerging microbes & infections · 2026Article
- A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery.Emerging microbes & infections · 2026Article
- Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species.Emerging microbes & infections · 2026Article
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- Multimodal Physicochemical Characterization of Cross-Linking Activities of Biparatopic Antibodies.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.Virology journal · 2025Article
- Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance.Biomolecules · 2025Review
- Evolutionary Insight into Fatal Human Coronaviruses (hCoVs) with a Focus on Circulating SARS-CoV-2 Variants Under Monitoring (VUMs).Biomedicines · 2025Review
- Bispecific antibody engineered from two non-protective antibodies confers full protection against anthrax toxin through inhibition of PA83 cleavage.Microbiology spectrum · 2025Article
- Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives.Molecular biology reports · 2025Review
- Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies.Molecular pharmaceutics · 2025Article
- Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses.iScience · 2025Article
- New mouse model for inducible hACE2 expression enables to dissect SARS-CoV-2 pathology beyond the respiratory system.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan-Sarbecoviruses.MedComm · 2025Article
- T-Cell-Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS-CoV-2 Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mapping Antibody Epitopes by Solution NMR Spectroscopy: Practical Considerations.Methods in molecular biology (Clifton, N.J.) · 2025Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
47 authors at 13 institutions in 6 countries.
Raoul De Gasparo *Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Mattia Pedotti *Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Luca SimonelliInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Petr NicklCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID http://orcid.org/0000-0002-4289-0502
Frauke MueckschLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0132-5101
Irene CassanitiMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Elena PercivalleMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Federica MazzolaInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Davide MagrìEuropean Commission, Joint Research Centre, Ispra, Italy.ORCID http://orcid.org/0000-0003-3790-5332
Tereza MichalcikovaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Jan HaviernikVeterinary Research Institute, Brno, Czech Republic.
Vaclav HonigVeterinary Research Institute, Brno, Czech Republic.ORCID http://orcid.org/0000-0003-0469-4604
Blanka MrazkovaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Natalie PolakovaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Andrea FortovaVeterinary Research Institute, Brno, Czech Republic.
Jolana TureckovaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Veronika IatsiukCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Salvatore Di GirolamoInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Martin PalusVeterinary Research Institute, Brno, Czech Republic.
Dagmar ZudovaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Petr BednarVeterinary Research Institute, Brno, Czech Republic.
Ivana BukovaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Filippo BianchiniInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland.
Dora MehnEuropean Commission, Joint Research Centre, Ispra, Italy.
Radim NenckaInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Petra StrakovaVeterinary Research Institute, Brno, Czech Republic.
Oto PavlisCenter of Biological Defense, Military Health Institute, Military Medical Agency, Techonin, Czech Republic.
Jan RozmanCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID http://orcid.org/0000-0002-8035-8904
Sabrina GioriaEuropean Commission, Joint Research Centre, Ispra, Italy.
Josè Camilla SammartinoMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Federica GiardinaMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Stefano GaiarsaMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Qiang Pan-HammarströmDepartment of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.ORCID http://orcid.org/0000-0003-1990-8804
Christopher O BarnesDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0002-2277-3990
Luigi CalzolaiEuropean Commission, Joint Research Centre, Ispra, Italy.ORCID http://orcid.org/0000-0002-8474-7974
Antonio PirallaMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID http://orcid.org/0000-0002-6062-2579
Fausto BaldantiMolecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2368-3719
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Jan ProchazkaCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Radislav SedlacekCzech Centre of Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID http://orcid.org/0000-0002-3352-392X
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland. drobbiani@irb.usi.ch.ORCID http://orcid.org/0000-0001-7379-3484
Daniel RuzekVeterinary Research Institute, Brno, Czech Republic. ruzekd@paru.cas.cz.ORCID http://orcid.org/0000-0003-4655-2380
Luca VaraniInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland. luca.varani@irb.usi.ch.ORCID http://orcid.org/0000-0002-0963-0987
Czech Academy of Sciences, Institute of Molecular Genetics · CZUniversità della Svizzera italiana · CHPoliclinico San Matteo Fondazione · ITVeterinary Research Institute · CZJoint Research Centre · ITRockefeller University · USCalifornia Institute of Technology · USHoward Hughes Medical Institute · USCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZInstitute of Parasitology of the Slovak Academy of Sciences · SKKarolinska Institutet · SEUniversity of Pavia · ITUniversity of South Bohemia in České Budějovice · CZ
Funding
Virus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI HOPE, THOMAS · 2019 to 2021
$14.9MUniversity of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MDiscovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9MHoward Hughes Medical InstituteNIAID NIH HHS P50 AI150464NIAID NIH HHS R01 AI078788NIAID NIH HHS R37 AI064003NIAID NIH HHS U01 AI151698NIH HHS 2U19AI111825NIH HHS P01-AI138398-S1
Abstract
Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-19
Indexed as
Angiotensin-Converting Enzyme 2AnimalsAntibodies, BispecificAntibodies, MonoclonalAntibodies, NeutralizingBody WeightCOVID-19COVID-19 Drug TreatmentDependovirusDisease Models, AnimalEpitopes, B-LymphocyteFemaleHumansImmune EvasionImmunoglobulin GMiceACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, BispecificAntibodies, MonoclonalAntibodies, NeutralizingEpitopes, B-LymphocyteImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.